TCM
LRMR icon

Teza Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Teza Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,094
Closed -$42K – 555
2016
Q4 		$42K Buy
+1,094
New +$44.4K 0.06% 225

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Teza Capital Management's LRMR Position: Q1 2017 in Review

Teza Capital Management sold out of Larimar Therapeutics (LRMR) in Q1 2017, closing a stake of 1,094 shares — an estimated $42K sold.

Teza Capital Management first reported a position in LRMR in Q4 2016 and held it in 1 quarter. The position peaked at $42K in Q4 2016. 80 funds tracked by Wall St. Rank hold LRMR as of Q1 2017.

  • Teza Capital Management reported no remaining Larimar Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Teza Capital Management sold 1,094 Larimar Therapeutics shares in Q1 2017, an estimated $42K.
  • Teza Capital Management first reported a position in Larimar Therapeutics in Q4 2016 and held it in 1 quarter.
  • Teza Capital Management's Larimar Therapeutics position peaked at $42K in Q4 2016.
  • 80 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2017.

Based on Teza Capital Management's 13F filing for Q1 2017, filed 4 May 2017.